Other research analysts have also recently issued research reports about the stock. Oppenheimer raised their price target on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, November 25th. Roth Capital raised their price target on shares of Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Canaccord Genuity raised their price target on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a report on Wednesday, November 20th. TheStreet raised shares of Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Finally, Zacks Investment Research cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 30th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $71.38.
Shares of NASDAQ:CRSP opened at $59.90 on Friday. The firm’s 50 day simple moving average is $65.94 and its 200-day simple moving average is $51.65. Crispr Therapeutics has a one year low of $29.34 and a one year high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. As a group, equities analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. Insiders sold 56,118 shares of company stock valued at $3,620,760 in the last ninety days. 21.40% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in CRSP. Nikko Asset Management Americas Inc. grew its position in shares of Crispr Therapeutics by 48.4% in the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after purchasing an additional 906,006 shares during the period. Orbimed Advisors LLC acquired a new position in Crispr Therapeutics during the third quarter worth about $21,167,000. Price T Rowe Associates Inc. MD boosted its position in Crispr Therapeutics by 19.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after acquiring an additional 121,176 shares during the last quarter. Balyasny Asset Management LLC acquired a new position in Crispr Therapeutics during the second quarter worth about $5,165,000. Finally, Millennium Management LLC acquired a new position in Crispr Therapeutics during the third quarter worth about $4,366,000. Institutional investors and hedge funds own 49.82% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: Sell-Side Analysts
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.